Clungene® COVID-19 Antigen Rapid Test Cassette
Even with following the regulations (wearing a mask, keeping a social distance), you might have to face coronavirus infections at your company or in your public institution. Mass testing is essential in that case. This is the only way to get a full picture of the extent of the danger. The Clungene® COVID-19 rapid test is practical and affordable, and your company doctor can perform in-house testing on your co-workers.
The key to prevention
The antigen rapid test is a perfect complement to the IgG/IgM rapid test also available in our web shop. If the IgG/IgM test is positive, it is worth to check and confirm the result with an antigen test. The Antigen Rapid Test Cassette also helps monitor contact persons and provides reliable information if someone at your company shows symptoms specific to COVID-19.
By using IgG/IgM and antigen test combined, you can always have a clear picture of the current state of your employees’ health. This is essential if you want to avoid the shutdown and or mass sick pays. With your company having an own test kit, you will not be exposed to the test capacity of the state healthcare, not to mention waitlists and possible test shortages.
How the antigen rapid test works
Like every virus, SARS-CoV-2 has a unique protein too. Our immune system recognizes the virus based on this protein and starts the defend by producing antibodies. Similar to the PCR test, the antigen test also identifies the presence of the protein. It means, that this test is able to directly detect the presence of the virus in the human body. It is important to know that the detection of the antigens is only possible for 7 days after the symptoms have appeared. Testing should be done at this time.
Benefits:
The CLUNGENE Covid-19 antigen rapid test is a lateral flow immunoassay for the qualitative detection of an acute SARS-CoV-2 infection. The rapid test is delivered with the necessary accessories and can be carried out at the point of care. The results can be read 15 minutes after specimen application. No cross-reactivity with influenza viruses and human coronaviruses (229E, OC43, NL63, HKU1) has been detected.
The test is designed to detect SARS-CoV-2 nucleocapsid antigens in nasal, nasopharyngeal and oropharyngeal swab specimens
Nasopharyngeal specimens are collected by inserting a swab into the nose to collect the specimen from the posterior wall of the nasopharynx. Oropharyngeal specimens are collected by inserting a swab into the posterior pharynx and tonsillar areas and rubbing over both tonsillar pillars and the posterior oropharynx.
The nasal swab is taken from the nasal mucosa - to do this, the swab is inserted approx. 2.5 cm into the nostril and passed along the nasal mucosa several times. The procedure is repeated with the same swab in the other nostril.
The antigen test is suitable for the detection of the following variants: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37) and Omicron (B.1.1.529)